Literature DB >> 15514421

Riluzole augmentation for treatment-resistant depression.

Gerard Sanacora, Steven F Kendell, Lisa Fenton, Vladimir Coric, John H Krystal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15514421     DOI： 10.1176/appi.ajp.161.11.2132

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  24 in total

Review 1.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

2.  N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.

Authors:  Daniel L Lafleur; Christopher Pittenger; Ben Kelmendi; Tom Gardner; Suzanne Wasylink; Robert T Malison; Gerard Sanacora; John H Krystal; Vladimir Coric
Journal:  Psychopharmacology (Berl)       Date:  2005-12-22       Impact factor: 4.530

Review 3.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

Review 4.  Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.

Authors:  Marc S Lener; Bashkim Kadriu; Carlos A Zarate
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

5.  Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.

Authors:  Gerard Sanacora; Steven F Kendell; Yael Levin; Arthur A Simen; Lisa R Fenton; Vladimir Coric; John H Krystal
Journal:  Biol Psychiatry       Date:  2006-12-04       Impact factor: 13.382

6.  Riluzole and D-amphetamine interactions in humans.

Authors:  Mehmet Sofuoglu; Andrew J Waters; Marc Mooney; Thomas Kosten
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-05-18       Impact factor: 5.067

Review 7.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 8.  Brain imaging in pediatric obsessive-compulsive disorder.

Authors:  Frank P MacMaster; Joseph O'Neill; David R Rosenberg
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-11       Impact factor: 8.829

Review 9.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder.

Authors:  Sanjay J Mathew; Rebecca B Price; Xiangling Mao; Eric L P Smith; Jeremy D Coplan; Dennis S Charney; Dikoma C Shungu
Journal:  Biol Psychiatry       Date:  2007-10-29       Impact factor: 13.382
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.